FDA Approves Novoeight

NovoEight (turoctocog alfa) Receives Approval from the FDA

Bagsværd, Denmark, 16 October 2013 – Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics License Application (BLA) for recombinant coagulation factor VIII, Novoeight.

The FDA approved Novoeight for use in adults and children with hemophilia A for:

  • Control and prevention of bleeding
  • Perioperative management
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight has been studied in the guardian™ clinical programme; one of the largest and most comprehensive pre-registration clinical trial programmes in the field of hemophilia therapy with more than 210 severe hemophilia A patients. In the completed trials Novoeight® demonstrated good efficacy in preventing and treating bleeds and had no confirmed inhibitor development, and all patients in the surgery trial were treated effectively. Novoeight® will be launched with the newly introduced prefilled device, MixPro®.

“The approval of Novoeight® marks an important step in offering a new alternative for people with hemophilia A, and demonstrates our commitment to hemophilia,” says Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk.

Awaiting the expiration of existing patents, Novo Nordisk plans to launch in the U.S. Novoeight® shortly after April 2015.

Novoeight® received positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in September 2013. Applications for regulatory approval have also been submitted in a range of other countries.

About Hemophilia A

Hemophilia is a chronic, inherited bleeding disorder that primarily affects males. People with hemophilia A are either missing or have a malfunctioning factor VIII protein, which is essential for proper blood clotting. People with hemophilia A have a tendency to bleed longer than most, or to bleed internally, because they are missing this clotting factor. To manage the disease and stop bleeding, people with hemophilia A must replace the missing factor VIII protein through intravenous injection of the clotting factor.

Globally it is estimated that 350,000 people have hemophilia A. The disease is severely under-diagnosed in developing countries.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 36,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge
 +45 4442 3450
 amhg@novonordisk.com

Ken Inchausti (US)
 +1 609 514 8316
 kiau@novonordisk.com

Investors:

Kasper Roseeuw Poulsen
 +45 4442 4303
 krop@novonordisk.com

Frank Daniel Mersebach
 +45 4442 0604
 fdni@novonordisk.com

Lars Borup Jacobsen
 +45 3075 3479
 lbpj@novonordisk.com

Daniel Bohsen
 +45 3079 6376
 dabo@novonordisk.com

Jannick Lindegaard (US)
 +1 609 786 4575
 jlis@novonordisk.com
 

Posted: October 2013

Novoeight (turoctocog alfa) FDA Approval History

View comments

Hide
(web1)